Incyte Q3 2021 Earnings Call Transcript

Quartr
Provided by Quartr
November 1, 2021

Key Takeaways

  • Incyte reported Q3 product and royalty revenues of €778 million, up 25% year-over-year and nearly 50% since Q3 2019, driven by an expanded product portfolio (from 3 to 7 approved drugs).
  • The newly launched Opselura (topical JAK inhibitor for mild-to-moderate atopic dermatitis) shipped ~3,000 tubes in its first four weeks, with 76% target HCP engagement and 61,000 website users; broad payer coverage is expected by Q1 2022.
  • Jakafi sales grew 12% to $547 million in Q3, and full-year guidance of $2.125–2.17 billion was reiterated; the recent approval for steroid-refractory chronic GVHD opens ~14,000 additional patients.
  • The FDA accepted the NDA for parsaclisib in relapsed/refractory marginal zone, mantle cell, and follicular lymphomas (PDUFA dates April 30 and August 30 2022), after strong response rates (57–75%) and manageable safety.
  • Positive Phase 3 TRuV data for ruxolitinib cream in vitiligo showed significant repigmentation at 24 weeks, with EMA MAA validation and US sNDA in progress, positioning another dermatology growth opportunity.
AI Generated. May Contain Errors.
Earnings Conference Call
Incyte Q3 2021
00:00 / 00:00

There are 15 speakers on the call.

Operator

Hello, and welcome to the Incyte Third Quarter 2021 Earnings Calling Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Christine Cho, Head of Investor Relations.

Operator

Please go ahead.

Speaker 1

Thank you, Kevin. Good morning, and welcome to Incyte's 3rd Quarter 2021 Earnings Conference Call and Webcast. The slides presented today are available for download on the Investors section of our website. Joining me on the call today are Herve, Barry, Steven and Christiana, who will deliver our prepared remarks and Dash, who will join us for the Q and A. Before we begin, I'd like to remind you that some of the statements made during the call today are forward looking statements and are subject to a number of risks and uncertainties That may cause our actual results to differ materially, including those described in our 10 Q for the period ended June 30, 2021, and from time to time in our other SEC documents.

Speaker 1

We will now begin the call with Herve.

Speaker 2

Thank you, Christine, and good morning, everyone. I'm happy to report today on an important quarter for Insight. But before we do that, I would like to take a moment to speak about the significant transformation our company has undergone over the past 2 years. From the Q3 of 2019 to today, Incyte has more than doubled its number of approved products from 3 to 7 And has increased the number of approved indications from 5 to 12, a significant achievement for patients around the world. Within the same time period, quarterly product and royalty revenues have grown nearly 50% from €534,000,000 778,000,000 in the most recent quarter.

Speaker 2

The 778,000,000 Product and royalty revenue for Q3 2021 does not yet reflect revenue contribution from our 2 most recent U. S. Approval, Opselura in atopic dermatitis and Jakafi in steroid refractory chronic GvHD. In addition, we expect further growth We'll expand to other countries as reimbursement is secure. As you see on Slide 5, we have provided long term guidance for some of this product And there is significant upside to the current sales number.

Speaker 2

Within hematology oncology, our MPN GVHD franchise, which includes Jakafi and other innovation, is Expected to surpass $3,000,000,000 in peak sales. Additionally, MONGV, approved for the treatment of relapsed Our refractory DLBCL has the potential to reach $500,000,000 in this indication in the U. S. While we have not provided guidance In Minjuvie, Pemazie and IQOSIC, this product represents additional growth potential and generates further value to our business. Turning to dermatology.

Speaker 2

Over the past year, we have successfully established our dermatology commercial franchise in the U. S. Given the product profile of Opselor and the talented commercial team we have in place, we are confident in the potential for Opselor and we expect peak sales To reach at least 1,500,000,000 in the United States in atopic dermatitis. While still very early in the launch of Optera, the initial uptake has been Strong and Barry will be providing details in his prepared remarks. Looking ahead in two other areas of our portfolio, we are Multiple regulatory decision in 2022, including ruxolitinib Cream in Vitiligo in both the U.

Speaker 2

S. And Europe, pafaclasib in 3 non Hodgkin lymphoma indications in the U. S. As well as once daily ruxolitinib late in 2022 or early 2023. This 2022 regulatory decision, which closely follow multiple product approval in 2021, Position us well for further growth and diversification of our product revenues in the coming year.

Speaker 2

Our partners are also making headway. With Novartis, ruxolitinib is currently under review in Europe and Japan for acute and chronic GvHD and capmatinib is under review in Europe for non small cell lung cancer. In addition, Geely is planning to submit an sNDA to the FDA for paracetinib in alopecia areata by the end of this year. If approved, these opportunities will provide valuable growth to our royalty revenues, which have already surpassed $400,000,000 during the 1st 9 months of this As you have seen, 2021 has been an important year of commercial, clinical and regulatory success for Incyte. With that, I will hand over to Barry to cover the individual product performance.

Speaker 3

Thank you, Herve, and good morning, everyone. Jakafi sales grew 12% year over year to reach $547,000,000 for the quarter, and we are reiterating our full year guidance range of 2.12 $5,000,000,000 to $2,170,000,000 Jakafi was the 1st approved treatment In myelofibrosis, polycythemia vera and steroid refractory acute GVHD and years later remains the standard of care in each of these indications. Growth across MF, PD and GvHD continues to be strong. And as you can see on the left, New patient starts have returned to pre pandemic levels. With patients staying on therapy longer and new patients coming in, The total number of patients on Jakafi continues to increase year over year.

Speaker 3

Myelofibrosis patients, the largest Proportion of patients on Jakafi comprise 45% of total patients, while polycythemia vera and GvHD patients accounts for 34% 14% of total patients respectively. At the end of September, Jakafi was approved for its 4th indication For the treatment of steroid refractory chronic GvHD. To put this reason of approval into perspective, approximately 2,000 patients with Graft versus host disease are currently using Jakafi, the majority of whom have acute form of the disease. There are over 14,000 patients We expect The recent approval to accelerate new patient starts with Jakavi. Turning to slide 8, MINJUVY sales grew 22% sequentially To $22,000,000 in the Q3 with growth driven primarily by demand.

Speaker 3

We are seeing an increase in the number of total accounts Across both academic and community settings and there has been a swift shift towards adoption of MONJUVY earlier in the treatment paradigm. We now have a greater proportion of MUNJUVY patients initiating therapy in the second line, which should result in patients experiencing longer and more durable responses, Leading to a longer duration of therapy. Feedback from healthcare professionals continues to be positive with efficacy, duration of response and safety being the key drivers of adoption. HCP awareness of MONJUVIA's differentiated profile continues to increase And the L MIND 3 year results have been well received by the physician community. As patients continue to return to the office And as our reps continue to educate healthcare professionals on the clinical profile of MINJUVY, we are confident in our ability to build on this improving momentum.

Speaker 3

Turning to Slide 9, we are very excited to receive the approval of OXOLOR, 1st FDA approved topical JAK inhibitor for the treatment of mild to moderate atopic dermatitis. Prior to launch, We had identified 11,000 dermatologists and high priority allergists, the top 20% of which are responsible for nearly 80% of atopic dermatitis Our patient assistance programs are in place to help reduce the barriers to access for Optolora Our negotiations with payers are advancing well. To date, we have made significant progress with our stakeholders in the launch of Upsilara. Since our launch on October 11, our field based representatives have actively engaged with 76% of our target prescribers and have conducted 8,500 HCP calls in the 1st 3 weeks of launch, of which 95% are being conducted in person. We're also receiving a significant amount of interest in Opselorra from patients.

Speaker 3

And in the 1st 2 weeks of launch, we have approximately 61,000 unique website users This number continues to climb. Further highlighting the level of engagement from patients, there were over 1500 Patient registrations for our co pay card program. And lastly, on the payer front, our discussions with PBMs, which include The top 3 who account for nearly 80% of commercially insured patients in the U. S. Have been very positive as they realize the value proposition of Opseloram.

Speaker 3

As a result, we expect to secure broad coverage in Q1 of next year. In the meantime, during this contracting period, We have multiple efforts underway to ensure patients are able to access their medication. Although it is still early in launch, Our efforts are translating into the first science of a very successful launch. As you know, there are limitations to the accuracy of script data. It's important to note that IQVIA's capture rate of prescriptions are under representative of actual demand, especially in the initial weeks of launch.

Speaker 3

Over time, the capture rate is expected to continue to improve. There are 2 different metrics that we're using to track performance Consisting of new brand new to brand RXs and 867 data. New RX data shown on the left Captures of patients who are either new to the market or have switched to OXELORA. In the 1st 2 weeks of launch, there have been close to 1,000 New to brand prescriptions, with nearly 2 thirds of scripts coming from patients who were previously on topical corticosteroid therapy. On the right hand side, we are showing 867 data, which is the number of units of OXO LR 60 gram tubes that our wholesalers are shipping to pharmacies.

Speaker 3

While 867 data doesn't translate directly into scripts, we believe it captures demand appropriately given the low level of inventory retail pharmacies Please hold for specialty dermatology products. Pharmacies order Opselorra when a prescription is received and approved by the patient's insurance or processed through our patient access programs. In its 3rd week of launch, 11 15 tubes of Optelora was shipped by wholesalers, bringing the total shipped since launch to over 2,200. Based on early data, we are now tracking towards 300 plus units shipped in the 1st 4 weeks of launch. Now I'll turn the call over to Stephen for a clinical update.

Speaker 4

Thank you, Barry, and good morning, everyone. The Q3 brought numerous achievements on both the clinical and regulatory fronts. Starting with the 3 recent regulatory approvals, MINJUVY was approved in Europe for 2nd line diffuse large B cell lymphoma in August. In September, OPZELURA was approved in the United States For mild to moderate atopic dermatitis, ANJAKIFI was approved in the United States for second line chronic graft versus host disease. In addition to these regulatory milestones and successes, we presented pivotal data from our Phase 3 TruV studies ruxolitinib in Vitiligo at the European Academy of Dermatology and Venereology.

Speaker 4

The full data set highlighted the significant improvements In facial and total body repigmentation seen in Vitiligo patients after treatment with ruxolitinib Cream. Also presented at EADV was positive pivotal data for baricitinib, our partnered product with Eli Lilly in alopecia areata. These data show that treatment with once daily baricitinib 4 milligrams was superior to placebo in achieving significant scalp hair regrowth 24 weeks in adults with severe alopecia areata. We also announced the global collaboration with Syndax Pharmaceuticals, which is pending regulatory clearance to develop and commercialize axotilumab, an anti CSF1 receptor monoclonal antibody for chronic graft versus host disease and other fibrotic diseases. Lastly, we recently announced the acceptance of the marketing authorization application By the European Medicines Agency, piroxolitinib Cream in Vitiligo and yesterday, we announced that the FDA accepted the NDA for paclitisib In 3 types of non Hodgkin's lymphomas.

Speaker 4

We received priority review for pacaklisaib in 2 of the indications, including for relapsed or refractory marginal zone lymphoma in adult patients who have received at least one prior anti CD20 based regimen and for mantle cell lymphoma The PDUFA date for these two indications is April 30, 2022. There will be a standard review for paciklisib in relapsed or refractory follicular lymphoma in adult patients who have received at least 2 prior systemic therapies With the PDUFA target action date of August 30, 2022. Let me remind you of the efficacy across non Hodgkin's lymphoma. In relapsed or refractory marginal zone lymphoma, response rates seen and independently reviewed were 57% with the duration of response and PFS Not yet reached. In mantle cell lymphoma, this was a 71% response rate with a duration of response of 9 months a PFS of 11.1 months.

Speaker 4

And in relapsed or refractory follicular lymphoma, there was a 75% overall response rate With a duration of response of 14.7 months and a PFS of 15.8 months, all this data is with the once daily regimen of 2.5 milligrams. Remember, this drug was designed to avoid hepatotoxicity associated with 1st generation PI3 kinase delta inhibitors, And thus, we have seen low rates of liver toxicity with less than a 5% rate of grade 3 ALT and AST elevations. In addition, cases of serious diarrhea and colitis were manageable and reversible. Turning to the next slide. The clinical development of Parziclusive in hemolytic anemia continues to progress with the Phase 3 study expected Start by the end of this year.

Speaker 4

The study will evaluate the efficacy and safety of paclitisib versus placebo with the primary endpoint of durable hemoglobin response At week 24, patients must have a diagnosis of primary warm antibody autoimmune hemolytic anemia. Hemoglobin levels of 7 to 10 grams per deciliter and a FASAD F score of less than or equal to 43. This program represents another significant opportunity to address an unmet medical need where there are currently no approved therapies for patients. Moving to our Limber Development Program. We have multiple studies ongoing looking to improve upon the standard of care in myelofibrosis, polycythemavira and graft versus host disease.

Speaker 4

We expect data and or regulatory action for a few of these programs by the end of 2022, including the NDA submission for the once daily formulation of ruxolitinib. We also recently entered into collaboration with Syndax For axotilumab, an anti CSF1 receptor monoclonal antibody, which is currently being evaluated as a monotherapy In 3rd line, chronic graft versus host disease. In addition, we will have the opportunity to evaluate axitilumab As a combination therapy with our JAK inhibitors, where the ultimate goal would be to arrive at a safe and effective combination It could lead to a steroid free regimen for chronic graft versus host disease. Turning to dermatology and ruxolitinib Cream in Vitiligo. The Phase 3 TRUV data presented at EADV showed meaningful superiority to vehicle with 30% of patients Achieving a facial VASI 75 at week 24, which is in line with our Phase 2 results.

Speaker 4

As a reminder, facial VASI 75 response In the Phase 2 trial, continued to improve with ruxolitinib Cream treatment with an over 51% response rate at week 52. We expect the 52 week data from the TRUV pivotal studies to be available in 2022. We are extremely encouraged by these positive results and the impact ruxolitinib Cream may have for patients living with vitiligo in the United States and Europe. The MAA was recently validated by the European Medicines Agency and the U. S.

Speaker 4

SNDA is in progress. Turning to Slide 18 and an update on our dermatology programs. We continue to focus on developing our dermatology pipeline with ruxolitinib Cream And INCB-fifty four thousand seven hundred and seven, an oral selective Janus Kinase 1 inhibitor. Multiple studies are ongoing with ruxolitinib cream in atopic dermatitis, including TRU AD3, a pivotal trial in atopic dermatitis in pediatric patients. In addition to our TRU V program in Vitiligo, we are also looking at 707 in a Phase 2 study in patients with non segmental Vitiligo With a body surface area of greater than or equal to 8%.

Speaker 4

Additional studies for 707 are currently underway in other indications, including 2 Phase 2 trials in higher adenitis suppurativa and prurigo nodularis. We look forward to updating you on these programs next year. In closing, we had a very successful quarter with a number of clinical and regulatory accomplishments, including 3 approvals. The FDA acceptance of an NDA for paciklisib as a treatment for 3 types of non Hodgkin's lymphomas and the EMA acceptance of the MAA For ruxolitinib Cream as a treatment for vitiligo. Later this week, we invite you to join an analyst and investor call to discuss our oral PD L1 program, including data for 86,550, which was accepted for presentation at the SITC Annual Congress on November 13.

Speaker 4

With that, I would like to turn the call over to Christiana for the financial update.

Speaker 5

Thank you, Stephen, and good morning, everyone. Our total product and royalty revenues for the Q3 were $778,000,000 representing a 25% increase over the Q3 of 2020. Total product and royalty revenues for the quarter are comprised of net product revenues of 5 $47,000,000 for Jakafi and $48,000,000 for other hematology oncology products. Royalty from Novartis of $95,000,000 for Jakavi and $3,000,000 for Tabrecta And royalties from Lilly of $87,000,000 from Olumiant. The 12% year over year growth in Jakafi net product sales Reflects higher patient demand across all indications and a continued recovery of new patient starts as we continue to emerge from the COVID-nineteen pandemic.

Speaker 5

The tripling of the Olumiant royalties is due primarily to the use of Olumiant for the treatment of COVID-nineteen. There are agreements with Lilly for global net of sales of Olumiant for the treatment of COVID-nineteen. We're entitled to receive royalties equal to the Base double digit rates applicable to all global net product sales, plus an additional 13% royalty. Moving on to our operating expenses on a GAAP basis. Ongoing R and D expenses of $331,000,000 for the 3rd quarter Increased 11% from the prior year period, primarily due to the progression of our pipeline.

Speaker 5

Our SG and A expense for the quarter of $191,000,000 increased 58% from the prior year quarter, Primarily due to our investments related to the establishment of the new dermatology commercial organization in the new U. S. And the related activities to support the launch of Upselura for atopic dermatitis. Our collaboration loss For the quarter was $9,000,000 which represents our 50% share of the U. S.

Speaker 5

Net commercialization loss for MONJUVY. This is comprised of total net product revenues of $22,000,000 and total operating expenses, including COGS And SG and A expenses of $40,000,000 Finally, our financial position continues to be strong as we ended the quarter with approximately 2 point $1,000,000,000 in cash and marketable securities. Moving on to our guidance for 2021, we are reiterating our revenue, COGS, R and D and SG and A guidance for the year. We remain confident in our full year guidance for Jakafi based on our continued recovery of new patient starts and the approval in steroid refractory chronic GvHD. Operator, that concludes our prepared remarks.

Operator

Our first question is coming from Tazeen Ahmad

Speaker 6

I'm going to focus On atopic derm, so it looks like out of the gate, as you mentioned, the metrics are looking pretty strong. And if you were to say right now, what is your biggest, I guess, roadblock to pick up? Is it getting On insurance formulary or is it just trying to educate doctors on the product? Thank you.

Speaker 3

Hi, it's Barry. Thanks, Tazeen. First thing I'd like to say is that I realized I said That we are going to ship, in my prepared remarks, 300 tubes of OXOLLORA in the 1st 4 weeks and of course I meant 3,000 tubes, which would actually make it On par or better than the last two launches in atopic dermatitis. So we expect those 3,000 shipments to pharmacies To actually translate into more than 3,000 prescriptions in the first full 4 weeks of our launch. So what patient population are they really looking at?

Speaker 3

It's just the indication essentially, patients who are 12 years or older. There's no difference. I've spoken to many dermatologists, and they're confident That they can use this drug in teens all the way up to the older adults. So the biggest roadblock, Patient access is always an interesting problem at the beginning of the launch, but in fact, I think we're making great headway there. And as I said in my prepared remarks, I think we will in fact have broad coverage in the Q1 of next year.

Speaker 3

As you know, when new products are launched, particularly products like this in dermatology, sometimes the big PBMs will just block you for 6 months or more, and we think we can overcome that as quickly as possible. We've presented many times To payers across the country, big and small payers with our clinical data and they're really impressed by the value That Opselor will provide to these patients. So, even though it is always a barrier, we're worried about patient access, I think we're going to be fine in the relatively near future. As you know, in fact, when they start a new year is really when You want to ensure that your formulary is fully blown out and all of your Customers know exactly what's going to be covered and what's on the formulary. So we think in the beginning of the year, we'll have good progress there.

Speaker 6

Thanks, Barry. And just to clarify, do you know how long it's taking from the time the doctor writes the script to the time the patient is receiving products in the early days of the launch?

Speaker 3

I don't. It's very early. I can't give you a medium or an average. Some patients are obviously have to have prior approval. Other patients go through our InsightCares patient assistance program.

Speaker 3

I'm sure some patients are getting it very quickly

Operator

Our next question today is coming from Brian Abrahams from RBC. Your line is now live.

Speaker 7

Hey guys, thanks so much for taking my question. I have a question on the MF dynamics overall. It looks like and life cycle, it looks like patient volume has been very Stable year over year in MF for Jakafi and you're seeing a lot of the growth being driven by the other indications. Just wondering if you could talk about, I guess, what goes into your Out your guidance in terms of overall market dynamics across the indications. And then, as we think about sort of longer term, You didn't talk too much about the ongoing Phase onetwo work for the Bet and Alka 2.

Speaker 7

I'm just sort of wondering Where those stand and your level of confidence that that can drive potential growth and durability in the MF indication? Thanks.

Speaker 3

Sure. This is Barry. I'll start and then hand it over to Stephen for a bit and I'll talk to where they stand. But as you can see from the slide that we showed, the remarkable thing about Jakafi is that month after month, year after year, the total number of patients on Jakafi continues to increase, Whether it's MF, PV or GVHD, the number of patients who are on MF and on MF for a very long period of time Our is amazing, in fact. We know that we've really only penetrated about 50% of the market.

Speaker 3

Our biggest competition is really watch and wait. So getting physicians to fully understand the survival benefit that Jakafi offers to myelofibrosis patients is really what our challenge is, and we know we're making headway All the time. As I said in my at the beginning of my prepared remarks that myelofibrosis, PV, GVHD, the standard of care is Jakafi and it will continue to be that way. PV patients, same thing. They continue to grow Year after year, month after month and GvHD, especially for chronic GvHD, we know is going to grow very well.

Speaker 3

Those patients are the prevalence of those patients are greater than the prevalence of acute GVHD patients and the chronic GVHD The patients stay on for a much longer period of time. So I'll hand it over to Stephen now for Beth now too.

Speaker 4

Thanks, Barry, Brian. Thanks for your questions. So let me deal with each separately. Firstly, I'll start with ELK 2, which is a mechanism now We have data in hand that we understand in more and more. So if you look at iron metabolism in humans, Hempcidin, the way it works is high levels of hepcidin inhibit iron absorption from the gastrointestinal tract and stop its Release from macrophages.

Speaker 4

So there's less iron available to make red blood cells. If you are able to inhibit that hepcidin pathway through an 2 inhibitor, ions released and made available, both from absorption and both from macrophages to make new red blood cells. And we've shown that this compound Does that from a mechanism of action point of view. So where we are so we're very excited about its potential. We're completing the monotherapy safety and then the combo safety, and then we'll be ready to make more decisions on the path forward in terms of more pivotal studies, Which, let me remind you, which I've said repeatedly, will hopefully address both the anemia of the underlying disorder, which we think is hepcidin mediated, Plus the anemia induced by ruxolitinib, which we also think is hepcidin mediated.

Speaker 4

And if we achieve both of those, you'll get the safety And then maintain ruxolitinib dose and enhance efficacy. So the program really has a lot of potential. We hope to have a recommended Phase 2 combo dose ready to go early next year and then make those decisions. For the BEP program, again, a compound we've had in our hands for a long time. Years ago, we dosed it To much higher multiples in patients with solid tumors and the dose limiting toxicity there as we know with that inhibitors was On target and with thrombocytopenia.

Speaker 4

We're now dosing it at 20%, 25% of where we were before, Gathering monotherapy safety in myeloproliferative neoplasm patients and then combo safety. And then we'll again, Just like with the O. P. Program, have to make decisions on where to go looking at the competitive space as well. Would we be looking, Given its profile at suboptimal patients and in addition would we consider first line.

Speaker 4

So those data sets For the monosafety and the combo safety will be available in 2022. And as soon as we're ready and put up on clinicaltrials.gov, we'll be able to show you our

Speaker 3

Thank you.

Operator

Our next question is coming from Cory Kasimov from JPMorgan. Your line is now live.

Speaker 8

Hey, good morning guys. Thank you for taking my questions. I wanted to go back To Obcellura, now that you're early on in the launch and deepened discussions with payers, curious if your thinking around Expectations for gross to net have changed at all, how we should be thinking about this short term and then kind of longer term trends on this front. And then the follow-up is, as we think ahead to the anticipated approval of OXELURA for Vitiligo, How did the tubes per patient likely differ for a typical patient in that setting versus atopic derm? Thank you.

Speaker 3

Hey, Corey, it's Barry. So what we're thinking about the gross to net is that What we said in the past is that long term, we anticipate the gross to net to be 25% to 50%. But in this quarter in particular and then as we move into next The gross to net will be much higher, just because of the MDC blocks and the patient assistance programs that we provide, the co pay assistance. And as you know, in this Therapeutic category, over time, the use of those programs declines as there's more broader coverage. So our gross to net We'll continue to improve.

Speaker 3

For Vitiligo, maybe I'll start out and hand over to Stephen. We know it's going to be greater. I think we forecasted perhaps we said that we think in atopic dermatitis, 3 or more tubes will be used Per year, 10 tubes per year perhaps for vitiligo. I forget exactly what the clinical trial What was how many tubes we got, but obviously we want to patients are going to use this for 24, 52 weeks and we'll see how much Further after that, but I'll let Stephen comment as well.

Speaker 4

Thanks, Barry. Thanks, Kari. The data in my prepared remarks For the TRUV Phase 3 studies thus far have completely replicated the Phase 2 data in terms of the facial VASI 75 at 20 We know from the 52 week and the 104 week long term follow-up On our Phase 2 studies, one of the phenomenons with treating Vitiligo is continued improvement over time. And in fact, most of the patients, the vast majority elected to go on to long term treatment in the long term safety extension Because of continued improvement. So what Barry is alluding to is continued use over time.

Speaker 4

And over a 1 year period, The current estimate is at least 10 to 11 60 gram tubes would be needed to achieve what I just spoke about.

Operator

Thank you. Our next question today is coming from Kripita Devarkanda from Chua Securities. Your line is now live.

Speaker 9

Hey, guys. Thank you so much for taking my question. So with the approval of Opelura in atopic derm and the regulatory progress And Vitiligo, it looks like the dermatology franchise is off to a great start now. You also have additional trials going on. Can you talk about how you're thinking about the future of the derm franchise?

Speaker 9

Given what you've already targeted with drugs, would you be looking for something Complement that or should we look expect something more broad? Thank you.

Speaker 2

Herve here and Stephen will speak about the specifics of what's going on in derm and beyond dermatology With our current portfolio, I mean, the whole idea from the beginning was that we do research and discovery of new product Somewhere in between immunology, inflammation and cancer. So some products are typically cancer product, But many of the products, targeted therapies, type of product, antibodies, etcetera, but many of the mechanism we are studying, in fact, have application outside of cancer. And that's where it came that's where it started. And what we see today when you look at the 10 plus mechanisms that we are studying in early studies is that they can have applications outside of cancer. That's what we found with Yes, it's Ricans.

Speaker 2

It's delta in hemolytic anemia. That's what we see in many dermatology indications. The goal is really to continue on that sort of follow the science type of approach. And obviously, because Dermatology or the skin is the largest immune organ, I guess. We see a lot of applications In dermatology in the short term, but it could also go in other type of inflammatory immune type of disease.

Speaker 2

So Maybe, Stephen, if you want to talk about it.

Speaker 4

Thank you, Herve and Kripa. Thanks for the question. So Herve is right. The way we view in dermatology, and I'm glad you called it a I'm glad you called it a franchise. Even from an R and D point of view, it's absolutely not a one and done.

Speaker 4

So there's life cycle management of the Cream itself ongoing within atopic dermatitis and some of the manifestations thereof like chronic hand eczema, etcetera. There's still questions to be asked and addressed in Vitiligo, including the what happens with in patients on for the long term With really good improvements in facial VASI 90 and beyond and what happens with withdrawal in those situations. And then beyond those indications, as Herve was alluding to, given the mechanism of action of the cream in terms of JAK STAT pathway, There are a number of other indications that we're extremely interested in addressing, which are actually relatively from an R and D point of view, certainly with an oncology context, Really easy to study in terms of time. So stay tuned. We view this now as a life cycle management opportunity With a scale that we can address in a very, very efficient manner.

Speaker 4

And then because dermis, as you also as others have said, they're alluding to become really to Incyte, both from an R and D and then a commercial point of view, it's beyond in terms of our other compounds. So I alluded to in my prepared remarks with 54, 707, our relatively JAK1 specific oral inhibitor that there are other indications for which we already have Really good Phase 2 data in higher adrenitis Suppurativa. We have an ongoing Phase 2b there in approximately 200 patients It will deliver data next year and then we can make a decision on what to do from a pivotal aspect. We're studying that compound in prurigo nodularis. Again, the mix of action is very relevant there.

Speaker 4

And then in my prepared remarks for non segmental Vitiligo with body surface areas Of total body surface area involvement of 8% or greater, we think the risk benefit may well be favorable for an oral JAK there. So you can see that derm thinking from an R and D point of view has expanded in an appropriate proportional way and it's relatively efficient So thanks for the question.

Speaker 9

Thank you so much. I appreciate all the color.

Operator

Thank you. Our next question today is coming from Salveen Richter from Goldman Sachs, your line is now live.

Speaker 10

Good morning. Thanks for taking my questions. So back to OXOLURA, could you just give us any Qualitative feedback you're getting on the launch and with regard to the safety profile and use in the context of which Population, so would they be looking to combinatorial use for instance? And then, in Vitiligo, Is there any change to the outlook for market opportunity here?

Speaker 3

Hi, Salveen. It's Barry. So regarding the safety and the black box, I guess you're alluding to is that dermatologists are very used to Explaining to patients the difference between a systemic product and a topical product, for most skin diseases, in fact, dermatologists would rather use Topical product, so they know that, for example, the safety profile between an oral JAK inhibitor and a topical JAK inhibitor is going to be very So they're very comfortable with that. As I said before, I've spoken to many dermatologists. We've gotten a lot of feedback from the field.

Speaker 3

There really hasn't been a pushback on the types of patients they're going to use this, OXOLORA in. So it's approved for the indication from 12 and over and that's what they're telling us they're going to use it for. In terms of Combo use, I don't know. Sometimes they do cycle through dermatologists will cycle through different therapies as they're trying to control patients With atopic dermatitis, but we can't say in the future of what they're going to do. In terms of vitiligo, it's a Game changer.

Speaker 3

It can change patients' lives and how they feel about themselves. It's the only drug that will be approved for Repigmentation of the skin and we really think that's going to be something that patients and dermatologists, health care providers will want to utilize because it is Such a unique treatment and is going to help maybe 100 of 1000 of patients, if not more, live a better life, I think.

Speaker 10

Thank you.

Operator

Thank you. Our next question is coming from Jay Olson from Oppenheimer. Your line is now live.

Speaker 11

Hey, thanks for taking the questions and congrats on the 3 Parsiclusive filings and acceptances. Can you comment on FDA's rationale for granting MCL and MZL priority reviews while FL received a standard review? And then on the last call, I think you mentioned that tumor agnostic program for parcyclicid would transition to a molecular defined approach. And I was wondering if you Have any more details on those plans? And then lastly, on BONJUVY, can you talk about any impact that you're Seeing from Polyvi, especially as it moves to the frontline setting and any feedback from physicians in terms of how they Compare those 2 drugs.

Speaker 11

Thank you.

Speaker 4

Jay, it's Steven. Thanks for your questions. On the past eclisib acceptance of Filing, so it's one of the biggest submissions I've ever been involved in, in a positive way because we submitted All three indications at the same time with the entire package, realizing that the diseases, although under the umbrella of non Hodgkin's lymphoma in general are different in terms of some of their pathophysiology and the way they behave. And that's exactly what happened in terms of the review Cycles you allude to. So for both marginal zone and mantle zone lymphoma, given the unmet medical need there, The FDA felt that they warrant a priority review and also given the data we've seen.

Speaker 4

For follicular, I think Their feeling is maybe it's a little more of a crowded space, less unmet medical need. But also, and I think very importantly, It's a condition that they want long, long term follow-up in terms of the responders. And I think that's what's driving the review cycle there being lengthened. Obviously, our intent is to try and march these through all at the same time and get them approved at the same time. But if they end up separating out follicular to get longer follow-up on the I think that's what's driving the standard review cycle there.

Speaker 4

In terms of your second question, I think you were alluding to pemigatinib's Tumagnostic program, our FGFR inhibitor, and we had a tumor agnostic study underway For patients either with FGFR2 driven arrangements or FGFR3 or any others. And what we saw within that program, although early in small numbers, is some encouraging signals In certain areas like, glioblastoma that felt to be more FGFR3 driven And like some areas of non small cell lung cancer that were more FGFR2 driven. And we felt that the likelihood of getting A wide Tumor agnostic indication was perhaps more limited and it was more efficient to stop the agnostic program enrolling and go at those exactly at those 2 histology directly. So there'll be Phase Two studies underway in both glioblastoma multiforme that's FGFR3 driven and then non small cell lung cancer It's FGFR2 driven. And then for your MINJUVY PolyVie question, I'll turn it to Barry.

Speaker 4

Thanks.

Speaker 3

Sure, Jay. So in terms of MYJUVY and how it relates to PLEVI, we think well, first of all, we're approved in the 2nd line setting for Diffuse large diffuse DLBCL patients. And we really think that our profile is always going to be attractive to patients and to physicians. In fact, perhaps as you know, believe we reported over the last two quarters that their sales have declined. And we actually believe that because we're continuing to make inroads there, but BELIEVE is approved in the 3rd line setting, we're approved second line setting, as far as moving to the first line for BELIEVE, if they do move to the first line, we haven't seen the data yet, but that wouldn't bother us.

Speaker 3

It actually gives us more faith that our frontline trial We'll be positive for these patients and that even if they're in the first line setting before we get there, We'd be the choice for the in the second line setting, going forward. But we really believe that if their study is positive in combination with R CHOP, Our study could be positive in combination with our job.

Speaker 11

Great. Thanks for taking the questions.

Operator

Thank you. Our next question today is coming from Mark Fromm from Cowen and Company. Your line is now live.

Speaker 12

Hi. Thanks for taking my questions. Maybe just start with one follow-up for Steven. On your comments of the ALK2, when you We're discussing that you've seen pathway engagement in the hepcidin pathway. Were you speaking just about iron release or have you seen rises in red blood cell count In that monotherapy trial.

Speaker 12

And then for Barry, maybe if you can give a little more granularity on what you Mean by broad access, I guess, one, have any meaningful contracts been signed yet or at least getting very close to finalization where maybe you can speak to What type of step edits you're expecting to be in those final agreements?

Speaker 4

Mark, it's Steven. Thanks for the question. So we have not presented publicly data yet On hemoglobin improvement, is that what you were asking directly? But we have demonstrated preclinically and then in clinical samples that it's Doing exactly what we wanted to do from an MOA point of view in terms of iron dynamics and ferritin. We don't have the clinical endpoint yet on rise in hemoglobin and hope the that will follow and we'll be able to present that next year to you.

Speaker 4

And then Barry can answer the second part.

Speaker 3

Sure. As far as negotiations with payers, like I said, they're ongoing. We think they're very positive. We think in the Q1, we'll actually have broader access. And so we're negotiating not Just with the large PBMs, but all of the regional payers that are important throughout the country.

Speaker 3

And so I'm very confident that we will in fact In the near term, signed contracts. But don't forget, patients do have access to the drug now, not just through our patient support program, but they're being paid for. You asked about stepatif. We think that this drug is going to be used after steroids and I think that's perfectly appropriate. We think in fact We have a very good situation where from steroids all the way up to systemics, all of those patients For mild to moderate disease, this will be the drug to use for them.

Speaker 3

And we know that thousands and thousands of patients have already failed steroids. So that patient population It's just there for us to, for them to begin to utilize a drug with the profile that, Upsilora has. So we're confident about Our future market access and we're confident that patients are getting drug now and we don't think that step edits will be a problem or if there is one step edit Just like in our label that should be used after prior topical therapy, that's exactly where it's going to be used and we're fine with that.

Operator

Thank you. Our next question is

Speaker 13

Maybe just a little color on the sample program. What size of the tubes that are being given? And are there any mechanics That the physician has to go through before giving a sample. Just trying to get a sense for how confident you are that the samples are going to be converted to paying

Speaker 3

Well, I'm not sure if I exactly understand your question, but the sample size are In fact, 5 grams, so it's a very small tube. Healthcare professionals don't really have to go through anything In order to utilize samples And we can decide.

Speaker 13

Okay. Right. Well, I'm just trying to so they don't have to have A longer term prescription to get the free sample initially?

Speaker 3

No, they don't have to no, they can just write prescriptions and many just write the prescriptions upfront right away. So what we did decide to do, in fact was to temporarily suspend Our sample program that we had a report for the samples of a texture problem. So we just temporarily decided to stop the samples right now and that we will in fact investigate The root cause of any texture problem, of course, we have to get the tube to be sent back to us. We have to verify lot numbers and that sort of thing. But we It was the best thing to do at this point to temporarily suspend once we figure out what that report really means, then we'll see if we can

Operator

Thank you. Our next question today is coming from Michael Schmidt from Guggenheim. Your line is now live.

Speaker 14

Hey, guys. Thanks for taking my questions. I just had a clarification on OXOLLURA and then one on Pembazir. On OXOLLURA, of the 3,000 tubes Shipt that you mentioned, is there any expected inventory in stocking or build up? Or is that expected to directly translate into And then on Pembazir, I guess just thinking about market dynamics And again, help us understand the opportunity in non small cell lung cancer and upcoming data disclosures for the Pemazur program.

Speaker 14

Thanks so much.

Speaker 3

Sure, Michael. So for the first one, 3,002 ships, no, I don't think there's really much inventory. I think all of those tubes shipped to pharmacies will be turned into prescriptions. The reason is simply that a drug like this, they don't keep on their shelf for a long period of time. They're going to make sure that in fact patients Have insurance coverage or they have access to the drug before they're going to order this from the wholesalers.

Speaker 3

So I don't think there's very much inventory there at all. There's inventory at each of the wholesaler sites that will eventually go out to pharmacies. In fact, most of these pharmacies are Independent pharmacies, so pharmacies that are very used to working with dermatologists as there is that's their Most of their practice, so that's actually very encouraging because the dermatologists like to work with their local pharmacy that's experienced in Working with dermatologists. As far as the pemigatinib goes, pemazir goes and the cholangiocarcinoma market in the United States, Sure. There's growth opportunities there.

Speaker 3

Obviously, we have a first line study. Moving into the first line setting would actually mean a whole lot to us. That we know that there's patients are being tested for FGFR2 alterations and rearrangements, but there could be more patients tested. So the more patients that are tested identify that they might have this FGFR2 alterations, then they would be candidates for Pembazir. So I think there is growth there, But it is, as you know, a very small patient population.

Speaker 3

And as far as the lung cancer patient population to go, we'll have to see. We'll have to see how many patients actually do have and FGFR alterations in lung cancer. And we'll see what the future opportunity is there as we continue to roll out our studies.

Operator

Thank you. We have time for one more question that comes from the line of Matt Phipps from William Blair. Your line is now live.

Speaker 4

Good morning, everyone. This is Rob Andrew on for Matt Phipps here. Just wanted to follow-up on the earlier question there Yes. On the sample products and the potential issue there, how is that sample product actually different from the prescription product, if at all? Are they produced Separately, and are there likely to be any issues with the commercial product at all?

Speaker 3

Thanks. So yes, they're produced differently. Obviously, it's a 5 gram tube. It takes different pressure to get into the 5 gram tube. So, there are separate batches and we've produced about 140,000 Of the samples, as far as the 60 gram, we're investigating all of the batches just to make sure that the texture and problem, If there is any, we can fix and address.

Speaker 3

We actually do have We're following up on information that was reported to us that we may actually have a texture problem With the 60 gram tube, but we're working through that right now, but we have to do a root cause analysis and we have Thousands of tubes out there and we have to know, get them back from the patients or from the healthcare providers, Have that analyzed, see what the storing conditions were. And once that analysis is done, then we'll go forward from there.

Operator

Thank you. We've reached the end of our question and answer session. And ladies and gentlemen, that does conclude today's teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.

Powered by Quartr